Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

A spokesperson for Hims did not immediately respond to a request for comment. The company previously said it was cooperating ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed the Federal Trade Commission has been investigating the telehealth ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

The summary covers recent significant developments in health news including Warren Buffett's Berkshire Hathaway's investment in UnitedHealth Group and the struggles of the UK's bioethanol industry due ...

U.S. equities were mixed at midday following the release of the July retail sales report, which came in as expected.

Oscar Health has a lot of opportunities with the growth of Health Reimbursement Arrangements. See why OSCR stock is a buy ...